Mono and dually decorated nanoliposomes for brain targeting, in vitro and in vivo studies

Pharmaceutical Research

Volumn 31, Issue 5, 2014, Pages 1275-1289

  Markoutsa, E ^a   Papadia, K ^a   Giannou, A D ^a   Spella, M ^a   Cagnotto, A ^b   Salmona, M ^b   Stathopoulos, G T ^a   Antimisiaris, S G ^a,c  

^a UNIVERSITY OF PATRAS   (Greece)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c INSTITUTE OF CHEMICAL ENGINEERING SCIENCES   (Greece)

Author keywords

brain; ligand; liposomes; live animal imaging; nanoparticle; proteins; serum; targeting

Indexed keywords

APOLIPOPROTEIN E3; DIMER; LIGAND; LIPOSOME; LOW DENSITY LIPOPROTEIN RECEPTOR; MONOMER; NANOPARTICLE; PEPTIDE DERIVATIVE; PLASMA PROTEIN; TRANSFERRIN; NANOMATERIAL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CELL VACUOLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG TARGETING; HUMAN; HUMAN CELL; HYDROPHILICITY; IMMOBILIZATION; IN VITRO STUDY; IN VIVO STUDY; LIPOPHILICITY; MICROVASCULAR ENDOTHELIAL CELL; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; TRANSCYTOSIS; BRAIN; METABOLISM; TRANSFORMED CELL LINE; TRANSMISSION ELECTRON MICROSCOPY; VASCULAR ENDOTHELIUM;

BLOOD-BRAIN BARRIER; BRAIN; CELL LINE, TRANSFORMED; ENDOTHELIUM, VASCULAR; HUMANS; IN VITRO TECHNIQUES; LIPOSOMES; MICROSCOPY, ELECTRON, TRANSMISSION; NANOSTRUCTURES;

EID: 84899523576     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1249-3     Document Type: Article

References (47)

1. Pardridge WM. Drug transport across the blood-brain barrier. J Cerebral Blood Flow Metabolism. 2012;32:1959-72.
2. Lu W, Xiong C, Zhang R, Shi L, Huang M, Zhang G, et al. Receptor-mediated transcytosis: A mechanism for active extravascular transport of nanoparticles in solid tumors. J Control Release. 2012;161:959-66.
3. Paliwal SR, Paliwa R, Agrawa GP, Vyas SP. Targeted breast cancer nanotherapeutics: options and opportunities with estrogen receptors. Critl Rev in Therap Drug Carrier Syst. 2012;29:421-46.
4. Ghosh SC, Neslihan AS, Klostergaard J. CD44: A validated target for improved delivery of cancer therapeutics. Exp Opinion on Therap Targets. 2012;16:635-50.
5. Jiang X, Sha X, Xin H, Chen L, Gao X, Wang X, et al. Self-aggregated pegylated poly (trimethylene carbonate) nanoparticles decorated with c(RGDyK) peptide for targeted paclitaxel delivery to integrin-rich tumors. Biomaterials. 2011;32:9457-69.
6. Wang Z, Yu Y, Dai W, Cui J, Wu H, Yuan L, et al. A specific peptide ligand-modified lipid nanoparticle carrier for the inhibition of tumor metastasis growth. Biomaterials. 2013;34(3):756-64.
7. Gomes-Da-Silva LC, Santos AO, Bimbo LM, Moura V, Ramalho JS, Pedroso De Lima MC, et al. Toward a siRNA-containing nanoparticle targeted to breast cancer cells and the tumor microenvironment. Int J Pharma. 2012;434:9-19.
8. Xin H, Sha X, Jiang X, Chen L, Law K, Gu J, et al. The brain targeting mechanism of Angiopep-conjugated poly(ethylene glycol)-co-poly(e{open}- caprolactone) nanoparticles. Biomaterials. 2012;33(5):1673-81.
9. Pardridge WM. Drug targeting to the brain. Pharm Res. 2007;24:1733-44.
10. Lalani J, Raichandani Y, Mathur R, Lalan M, Chutani K, Mishra AK, et al. Comparative receptor based brain delivery of tramadol-loaded poly(lactic-co-glycolic acid) nanoparticles. J Biomed Nanotech. 2012;8(6):918-27.
11. Xia H, Gao X, Gu G, Liu Z, Hu Q, Tu Y, et al. Penetration-functionalized PEG-PLA nanoparticles for brain drug delivery. Int J Pharmac. 2012;436:840-50.
12. López-Dávila V, Seifalian AM, Loizidou M. Organic nanocarriers for cancer drug delivery. Curr Opinion Pharmacol. 2012;12(4):414-9.
13. Antimisiaris SG, Kallinteri P, Fatouros D. Liposomes and drug delivery, In: S.C. Gad editor, Pharmaceutical Manufacturing Handbook Production and Processes, John Wiley & Sons, 2008, pp. 443-533.
14. Markoutsa E, Pampalakis G, Niarakis A, Romero IA, Weksler B, Couraud P-O, et al. Uptake and permeability studies of BBB-targeting immunoliposomes using the hCMEC/D3 cell line. Eur J Pharmaceut Biopharma. 2011;77(2):265-74.
15. Xiang Y, Liang L, Wang X, Wang J, Zhang X, Zhang Q. Chloride channel-mediated brain glioma targeting of chlorotoxin-modified doxorubicine-loaded liposomes. J Control Release. 2011;152:402-10.
16. Kluza E, Jacobs I, Hectors SJCG, Mayo KH, Griffoen AW, Strijkers GJ, et al. Dual-targeting of ανβ3 and galectin-1 improves the specificity of paramagnetic/fluorescent liposomes to tumor endothelium in vivo. J Control Release. 2012;158:207-14.
17. Ying X, Wen H, Lu W-L, Du J, Guo J, Tian W, et al. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. J Control Release. 2010;141(2):183-92.
18. Li Y, He H, Jia X, Lu W-L, Lou J, Wei Y. A dual-targeting nanocarrier based on poly(amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas. Biomaterials. 2012;33(15):3899-908.
19. Kibria G, Hatakeyama H, Ohga N, Hida K, Harashima H. Dual-ligand modification of PEGylated liposomes shows better selectivity and efficient gene delivery. J Control Release. 2011;153(2):141-8.
20. Bae S, Ma K, Kim TH, Lee ES, Oh KT, Park E-S, et al. Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types. Biomaterials. 2012;33(5):1536-46.
21. Gao H, Qian J, Cao S, Yang Z, Pang Z, Pan S, et al. Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles. Biomaterials. 2012;33(20):5115-23.
22. Papademetriou T, Garnacho C, Schuchman EH, Muro S. In vivo performance of polymer nanocarriers dually-targeted to epitopes of the same or different receptors. Biomaterials. 2013;34:3459-66.
23. Ulbrich K, Hekmatara T, Herbert E, Kreuter J. Transferrin- and transferring-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur J Pharm Biopharm. 2009;71:251-6.
24. Schnyder A, Huwyler J. Drug transport to brain with targeted Liposomes. NeuroRx. 2005;2:99-107.
25. Markoutsa E, Papadia K, Clemente C, Flores O, Antimisiaris SG. Anti-Aβ-MAb and dually decorated nanoliposomes: Effect of Aβ1-42 peptides on interaction with hCMEC/D3 cells. Eur J Pharm Biopharm. 2012;81(1):49-56.
26. Pardridge WM. Tyrosine hydroxylase replacement in experimental Parkinson's disease with transvascular gene therapy. NeuroRx. 2005;2(1):129-38.
27. Re F, Cambianica I, Zona C, Sesana S, Gregori M, Rigolio R, et al. Functionalization of liposomes with ApoE-derived peptides at different density affects cellular uptake and drug transport across a blood-brain barrier model. Nanomed Nanotech Biol Med. 2011;7(5):551-9.
28. Re F, Cambianica I, Sesana S, Salvati E, Cagnotto A, Salmona M, et al. Functionalization with ApoE-derived peptides enhances the interaction with brain capillary endothelial cells of nanoliposomes binding amyloid-beta peptide. J Biotechnol. 2010;156(4):341-6.
29. Salvati A, Pitek AS, Monopoli MP, Prapainop K, Baldelli Bombelli F, Hristov DR, et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nature Nanotech. 2013;8:137-43.
30. Weksler BB, Subileau EA, Perriere N, Charneau P, Holloway K, Leveque M, et al. Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J. 2005;19:1872-4.
31. Poller R, Gutman H, Krahenbuhl S, Weksler B, Romero I, Couraud PO, et al. The human brain endothelial cell line hCMEC/D3 as a human blood-brain barrier model for drug transport studies. J Neurochem. 2008;107:1358-68.
32. Brambilla D, Nicolas J, Le Droumaguet B, Andrieux K, Marsaud V, Couraud P-O, et al. Design of fluorescently tagged poly(alkyl cyanoacrylate) nanoparticles for human brain endothelial cell imaging. Chem Commun. 2010;46:2602-4.
33. Kaasgaard T, Mouritsen OG, Jørgensen K. Receptor mediated binding of avidin to polymer covered liposomes. J Liposome Res. 2001;11(1):31-42.
34. Stewart JCM. Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal Biochem. 1980;104:10-4.
35. Kokona M, Kallinteri P, Fatouros D, Antimisiaris SG. Stability of SUV liposomes in the presence of cholate salts and pancreatic lipases: effect of lipid composition. Eur J Pharm Sciences. 2000;9:245-52.
36. Zhang Y, Zhu C, Pardridge WM. Antisence gene therapy of brain cancer with an artificial virus gene delivery system. Mol Ther. 2002;6:67-72.
37. Tan PH, Manunta M, Ardjomand N, Xue SA, Larkin DF, Haskard DO, et al. Antibody targeted gene transfer to endothelium. J Gene Med. 2003;5:311-23.
38. Kalchenko V, Shivtiel S, Malina V, Lapid K, Haramati S, Lapidot T, et al. Use of lipophilic near-infrared dye in whole-body optical imaging of hematopoietic cell homing. J Biomed Opt. 2006;11(5):505-7.
39. Kreuter J. Influence of the surface properties on nanoparticle mediated transport of drugs to the brain. J Nanosci Nanotechnol. 2004;4:484-8.
40. Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch- Brandt C, et al. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target. 2002;10:317-25.
41. Chang J, Paillard A, Passirani C, Morille M, Benoit J-P, Betbeder D, et al. Transferrin adsorption onto PLGA nanoparticles governs their interaction with biological systems from blood circulation to brain cancer cells. Pharm Research. 2012;29(6):1495-505.
42. Elias DR, Poloukhtine A, Popik V, Tsourkas A. Effect of ligand density, receptor density, and nanoparticle size on cell targeting. Nanomed Nanotech Biol Med. 2012;9:194-201.
43. Zheng X, Cheung LS, Schroeder JA, Jiang L, Zohar Y. Cell receptor and surface ligand density effects on dynamic states of adhering circulating tumor cells. Lab Chip. 2011;11(20):3431-9.
44. Yuan H, Zhang S. Effects of particle size and ligand density on the kinetics of receptor-mediated endocytosis of nanoparticles. Appl Phys Lett. 2010;96(3):0337041-3.
45. Gunawan RC, Auguste DT. The role of antibody synergy and membrane fluidity in the vascular targeting of immunoliposomes. Biomaterials. 2010;31(5):900-7.
46. Srivastava RAK, Ito H, Hess M, Srivastava N, Schonfeld G. Regulation of low density lipoprotein receptor gene expression in HepG2 and Caco2 cells by palmitate, oleate, and 25-hydroxycholesterol. J Lipid Research. 1995;36:1434-46.
47. Keck CM, Jansch M, Müller RH. Protein adsorption patterns and analysis on IV Nanoemulsions - The key factor determining the organ distribution. Pharmaceutics. 2013;5:36-68.